These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38805313)

  • 41. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
    Bosi C; Bartha Á; Galbardi B; Notini G; Naldini MM; Licata L; Viale G; Mariani M; Pistilli B; Ali HR; André F; Piras M; Callari M; Barreca M; Locatelli A; Viganò L; Criscitiello C; Pusztai L; Curigliano G; Győrffy B; Dugo M; Bianchini G
    Eur J Cancer; 2023 Dec; 195():113379. PubMed ID: 37913680
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.
    Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M
    J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanisms of Resistance to Antibody-Drug Conjugates.
    Loganzo F; Sung M; Gerber HP
    Mol Cancer Ther; 2016 Dec; 15(12):2825-2834. PubMed ID: 27780876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
    Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
    J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biomarkers for Antibody-Drug Conjugates in Solid Tumors.
    Katrini J; Boldrini L; Santoro C; Valenza C; Trapani D; Curigliano G
    Mol Cancer Ther; 2024 Apr; 23(4):436-446. PubMed ID: 38363729
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer.
    Salifu I; Singh N; Berraondo M; Remon J; Salifu S; Severson E; Quintana A; Peiró S; Ramkissoon S; Vidal L; Chico I; Saini KS
    Cancer Treat Res Commun; 2023; 36():100713. PubMed ID: 37172552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon.
    Ahmed Y; Berenguer-Pina JJ; Mahgoub T
    Oncology; 2021; 99(10):673-680. PubMed ID: 34280931
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
    Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
    Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy.
    Aggarwal D; Yang J; Salam MA; Sengupta S; Al-Amin MY; Mustafa S; Khan MA; Huang X; Pawar JS
    Front Immunol; 2023; 14():1203073. PubMed ID: 37671162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The potential roles of antibody-drug conjugates in head and neck squamous cell carcinoma.
    Filippini DM; Le Tourneau C
    Curr Opin Oncol; 2024 May; 36(3):147-154. PubMed ID: 38573203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibody drug conjugates: Progress, pitfalls, and promises.
    Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
    Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ABBV-011, A Novel, Calicheamicin-Based Antibody-Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors.
    Wiedemeyer WR; Gavrilyuk J; Schammel A; Zhao X; Sarvaiya H; Pysz M; Gu C; You M; Isse K; Sullivan T; French D; Lee C; Dang AT; Zhang Z; Aujay M; Bankovich AJ; Vitorino P
    Mol Cancer Ther; 2022 Jun; 21(6):986-998. PubMed ID: 35642431
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
    Malik P; Phipps C; Edginton A; Blay J
    Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies.
    Xie H; Adjei AA
    J Thorac Oncol; 2019 Mar; 14(3):358-376. PubMed ID: 30599202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody-drug conjugates--an emerging class of cancer treatment.
    Diamantis N; Banerji U
    Br J Cancer; 2016 Feb; 114(4):362-7. PubMed ID: 26742008
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
    Chu Y; Zhou X; Wang X
    J Hematol Oncol; 2021 Jun; 14(1):88. PubMed ID: 34090506
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
    Deng S; Lin Z; Li W
    Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
    Kim JH; Chang IH
    Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.